Adamantiades - Behcet disease (ABD) in Northern Greece patients: Experience from a single center

Hippokratia

Volumn 11, Issue 4, 2007, Pages 210-215

  Boura, P ^a   Tselios, K ^a   Skendros, P ^a   Kamali, S ^a   Sarantopoulos, A ^a   Raptopoulou Gigi, M ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Adamantiades Behcet disease; Clinical manifestations; HLA B51; Pathergy

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA B51 ANTIGEN; INFLIXIMAB; METHYLPREDNISOLONE;

ADAMANTIADES BEHCET DISEASE; ADULT; ARTHRALGIA; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DISEASE SEVERITY; EYE DISEASE; FEMALE; GENITAL ULCER; GREECE; HLA TYPING; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOPATHOLOGY; MALE; MOUTH ULCER; SKIN MANIFESTATION; SYSTEMIC VASCULITIS; THROMBOPHLEBITIS; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

EID: 35348953111     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Yazici H, Yurdakul S, Hamuryudan V. Behcet's syndrome. Curr Opin Rheumatol 1999; 11: 53-57
2. Hippocrates. Endemic Diseases. Third Book. Case 7. Kaktos (Ed). 1993; 13: 209
3. Adamantiades B. Sur un cas d'iritis α hypopyon recidivante. Ann Ocul 1931; 168: 271-4
4. Behcet H. Uber rezidiverende aphthose durch ein virus verursachte Geschwure am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-7
5. International Study Group for Behηet's Disease. Criteria for diagnosis of Behηet's disease. Lancet 1990; 335: 1078-80
6. International Study Group for Behηet's Disease. Evaluation of diagnostic ("classification") criteria in Behηet's disease: towards internationally agreed criteria. Br J Rheumatol 1992; 31: 299-308
7. Suzuki Kurokawa M, Suzuki N. Behcet's Disease. Clin Exp Med 2004; 3: 10-20
8. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behηet's disease. Int J Dermatol 2003; 42: 346-51
9. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's Disease. Semin Arthritis Rheum 1998; 27: 197-217
10. Pipitone N, Boiardi L, Olivieri I, et al. Clinical manifestations of Behηet's disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol 2004; 22 (6 Suppl 36): S46-51
11. Gonzalez-Gay MA, Garcia-Porrua C, Branas F, et al. Epidemiologic and clinical aspects of Behcet's disease in a defined area of Northwestern Spain, 1988-1997. J Rheumatol 2000; 27(3): 703-7
12. Shahram F, Nadji A, Jamshidi AR, et al. Behcet's disease in Iran, analysis of 5059 cases. Arch Iranian Med 2004; 7: 9-14
13. Zouboulis CC, Diawari D, Kirch W, et al. Adamantiades-Behcet's disease in Germany: Data of the German Registry in 1966. In: VIIth International Conference on Behηet's Disease. Revue du Rheumatisme, English edition. 1996; 63: 538
14. Tugal-Tutkun J, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet's disease: An analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-80
15. Mamo FG. The rate of visual loss in Behcet's disease. Arch Ophthalmol 1970; 84: 451-2
16. Kaklamani VG, Kaklamanis PG. Treatment of Behcet's disease: an update. Semin Arthritis Rheum 2001; 30: 299-312
17. Sfikakis PP. Behηet's disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 2002; 61(2 suppl): ii51-ii53
18. Akman-Demir G, Serdaroglu P, Tasci B, et al. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. Brain 1999; 122: 2171-81
19. Boura P, Tselios K, Kamali S, et al. Concurrent relapsing central nervous system and ocular involvement in a case of life-threatening Adamantiades-Behcet disease (ABD). Neurol Sci 2006; 27: 432-5
20. Monastero R, Camarda C, Pipia C, et al. Cognitive impairment in Behcet's disease patients without overt neurological involvement. J Neurol Sci 2004; 220: 99-104
21. Kandolf-Sekulovic L, Pavlovic MD, Glisic B, et al. Adamantiades-Behcet's disease, deep venous thrombosis and anticardiolipin antibodies: report of two cases. J Eur Acad Dermatol Venereol 2005; 19: 484-6
22. Coskun B, Saral Y, Godekmerdan A, et al. Activation markers in Behcet's disease. Skin Med 2005; 4: 282-6
23. Gur-Toy G, Lenk N, Yalcin B, et al. Serum IL-8 as a serologic marker of activity in Behcet's disease. Int J Dermatol 2005; 44: 657-60
24. Fietta P. Behcet disease: familial clustering and immunogenetics. Clin Exp Rheumatol 2005; 23 (4 Suppl 38): S96-105
25. Koumantaki Y, Stavropoulos C, Spyropoulou M, et al. HLA-B*5101 in Greek patients with Behcet's disease. Hum Immunol 1998; 59 250-5
26. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece. Clin Exp Rheumatol 2003; 21 Suppl 30: S19-26
27. Yazici H. Behcet's disease: an update. Curr Rheumatol Rev 2003; 5: 195-9
28. Kontogiannis V, Powell RJ. Behcet's disease. Postgrad Med J 2000; 76: 629-37
29. Haghighi AB, Pourmand R, Nikseresht AR. Neuro-Behcet Disease. A Review. The Neurologist 2005; 11: 80-9
30. Sfikakis PP, Theodosiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-6